Project Purple awarded our lab with a grant to study pancreatic ductal adenocarcinoma and determine what causes immunosuppression in patients with pancreatic cancer. This project was in collaboration with Dr. Dafna Bar-Sagi. A professor in the Department of Biochemistry and Molecular Pharmacology as well as the Department of Medicine Office of Science and Research at NYU.
Our group was awarded a Research Scholar Grant from the American Cancer Society to study the effects of Parp inhibition in pancreatic cancer. This work took lpace in the Mouse Hospital and explored the determinants and mechanisms of response to treatment with PARP inhibitors.
Ken Olive received the 2011 Lustgarten Foundation Translational Innovator Award. This one-year grant supported a preclinical trial to evaluate analogs of Erastin, a compound that is synthetic lethal with mutant Ras. Erastin was identified in 2001 by Dr. Brent Stockwell, an Associate Professor in the Department of Biology at Columbia University. This project represents an exciting collaboration that pairs the chemical biology expertise of the Stockwell group and the translational therapeutics expertise of the Olive group.
Ken Olive was awarded the 2011 AACR-PanCAN Career Development Award. This award supported investigations into the role and effects of hypoxia in the development and progression of pancreatic cancer.
The Olive Lab is supported by various grants from the National Cancer Institute, of the National Institutes of Health.
Ken Olive was named the 2010 Bernard A. Schwartz Designated Research Scholar in Pancreatic Cancer by the American Gastroenterological Association. This grant supports investigations into ability of Smoothened inhibitors to suppress pancreatic cancer metastasis. The AGA provided the first external support for the Olive, for which we are extremely grateful.
The Pancreas Center is a center of excellence dedicated to decreasing the burden of pancreatic cancer; the Pancreas Center provides outstanding medical care, undertakes breakthrough research, pioneers prevention and early detection techniques, educates patients and clinicians, and trains physicians to become experts in the treatment of pancreatic cancer, all with the goal of making the disease a controllable illness.
The Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University is dedicated to the cure of cancer through innovative research, training of researchers and clinicians, and outstanding patient care. In partnership with NewYork-Presbyterian Hospital, ranked as one of the top hospitals in the United States, the internationally-recognized researchers and clinicians of the HICCC bring together the best approaches for prevention, diagnosis and treatment of all types of cancer.
The Columbia University Department of Medicine has been committed to excellence in teaching, research, and patient care since its founding as part of King’s College (later Columbia University) in 1767. We are a diverse department with thirteen divisions. We maintain a dedicated and outstanding faculty of over 1300 physicians and scientists, train an outstanding housestaff of about 200 (including research fellows and students), and retain a support staff of approximately 350. We are the largest clinical department in the College of Physicians & Surgeons, with a budget close to $130 million.
We were awarded the Gray Foundation Team Science award which supported our BRCA2 research. Our team consisted of various labs specializing in cancer genomics and PDAC.